Sanofi Lays Off 229 Employees After Blueprint Medicines Deal
Under new CEO Belén Garijo, Sanofi disclosed its first major workforce reduction, laying off 229 employees tied to its 2025 acquisition of Blueprint Medicines. The move represents a targeted staffing cut stemming from the acquired company rather than a broader external regulatory or legal action, with the impact largely concentrated on affected employees.